Suppression of premature termination codons as a therapeutic approach
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
In this review, we describe our current understanding of translation termination and pharmacological agents that influence the accuracy of this process. A number of drugs have been identified that induce suppression of translation termination at in-frame premature termination codons (PTCs; also known as nonsense mutations) in mammalian cells. We discuss efforts to utilize these drugs to suppress disease-causing PTCs that result in the loss of protein expression and function. In-frame PTCs represent a genotypic subset of mutations that make up ~11% of all known mutations that cause genetic diseases, and millions of patients have diseases attributable to PTCs. Current approaches aimed at reducing the efficiency of translation termination at PTCs (referred to as PTC suppression therapy) have the goal of alleviating the phenotypic consequences of a wide range of genetic diseases. Suppression therapy is currently in clinical trials for treatment of several genetic diseases caused by PTCs, and preliminary results suggest that some patients have shown clinical improvements. While current progress is promising, we discuss various approaches that may further enhance the efficiency of this novel therapeutic approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Molecular Basis of Muscular Dystrophy in the mdx Mouse: a Point Mutation
Sicinski, P., Geng, Y., Ryder-Cook, A. S., Barnard, E. A., Darlison, M. G., & Barnard, P. J. (1989) · Science · doi:10.1126/science.2662404 · Cited by 1,276
Recognition of Cognate Transfer RNA by the 30 S Ribosomal Subunit
Ogle, J. M., Brodersen, D. E., Clemons, W. M., Tarry, M. J., Carter, A. P., & Ramakrishnan, V. (2001) · Science · doi:10.1126/science.1060612 · Cited by 1,162
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088 · cited 1×
“VX-809 was developed for CF patients with the Class II mutation F508del that affects CFTR trafficking (Van Goor et al., 2011), and VX-770 (Kalydeco®) was developed for the Class III mutation G551D that produces correctly localized CFTR, but causes channel gating defects (Van Goor et al., 2009).”
Fourmy, D., Recht, M. I., Blanchard, S. C., & Puglisi, J. D. (1996) · Science · doi:10.1126/science.274.5291.1367 · Cited by 829 · cited 1×
“Aminoglycoside binding induces a similar rearrangement of A1492 and A1493 in the absence of a tRNA in the A site (Fourmy et al., 1996) (Figure 3).”
Translational termination efficiency in mammals is influenced by the base following the stop codon
McCaughan, K. K., Brown, C. M., Dalphin, M. E., Berry, M. J., & Tate, W. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5431 · Cited by 284
GTP Hydrolysis by eRF3 Facilitates Stop Codon Decoding during Eukaryotic Translation Termination
Salas-Marco, J., & Bedwell, D. M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7769-7778.2004 · Cited by 200
Self-citationBrown, C. M., Stockwell, P. A., Trotman, C. N. A., & Tate, W. P. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.21.6339 · Cited by 191
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies
Schiffelers, R. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.3.333 · Cited by 163 · cited 1×
“Encapsulation of amikacin or gentamicin into conventional liposomes resulted in their rapid clearing from the bloodstream by the mononuclear phagocyte system (Schiffelers et al., 2001).”
Cited by
Ribosome-targeting antibiotics and mechanisms of bacterial resistance
Wilson, D. N. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3155 · Cited by 1,054
Mechanism and regulation of the nonsense-mediated decay pathway
Hug, N., Longman, D., & Cáceres, J. F. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw010 · Cited by 535
“A number of drugs have been identified that induce suppression of translation termination at PTCs in mammalian cells (163,164).”
BackgroundThe structure of the human mitochondrial ribosome
Amunts, A., Brown, A., Toots, J., Scheres, S. H. W., & Ramakrishnan, V. (2015) · Science · doi:10.1126/science.aaa1193 · Cited by 533
Amikacin: Uses, Resistance, and Prospects for Inhibition
Ramirez, M., & Tolmasky, M. (2017) · Molecules · doi:10.3390/molecules22122267 · Cited by 265
Schneider, N., Sundaresan, Y., Gopalakrishnan, P., Beryozkin, A., Hanany, M., Levanon, E. Y., Banin, E., Ben-Aroya, S., & Sharon, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101029 · Cited by 224
Metadata
- Authors
- Keeling, K. M., Wang, D., Conard, S. E., & Bedwell, D. M.
- Venue
- Critical Reviews in Biochemistry and Molecular Biology
- Publisher
- Informa UK Limited
- Published
- 2012-06-07
- Volume
- 47
- Issue
- 5
- Pages
- 444-463
- ISSN
- 0045-6411 (ISSN-L)
- 1040-9238
- 1549-7798
- OpenAlex
- W2018768650
- Cited by
- 111
- References
- 8
- FWCI
- 0.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Suppression of premature termination codons as a therapeutic approach. https://app.cochat.ai/papers/10.3109/10409238.2012.694846
- The paper
- Keeling, K. M., Wang, D., Conard, S. E., & Bedwell, D. M. (2012). Suppression of premature termination codons as a therapeutic approach. Critical Reviews in Biochemistry and Molecular Biology. https://doi.org/10.3109/10409238.2012.694846
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.